The severity of symptoms is insufficient to predict major alterations to quality of life of patients with fecal incontinence or chronic constipation.


Journal

International journal of colorectal disease
ISSN: 1432-1262
Titre abrégé: Int J Colorectal Dis
Pays: Germany
ID NLM: 8607899

Informations de publication

Date de publication:
Nov 2020
Historique:
accepted: 30 06 2020
pubmed: 7 7 2020
medline: 24 6 2021
entrez: 7 7 2020
Statut: ppublish

Résumé

Evaluate the impact of fecal incontinence (FI) and chronic constipation (CC) on the quality of life (QoL) in a large population and determine if a threshold of symptom scores was associated with alterations to QoL. A total of 422 outpatients with FI (n = 186), CC (n = 186), and mixed FI-CC (n = 50) referred for anorectal manometry were included prospectively. All patients completed a set of questionnaires to evaluate the severity of FI and CC (respectively Jorge and Wexner and KESS scores) and their impact on QoL (Gastrointestinal Quality of Life Index (GIQLI)). The study population included 81.8% women. The QoL was altered to the same degree for both FI and CC, with significant more marked impairments in patients with mixed FI-CC (median GIQLI: 91 (71-108) vs. 91 (73-108) vs. 81 (57-97) respectively, p = 0.05). The symptom severity significantly but weekly correlated with the GIQLI score (r The QoL was equally altered for FI and CC. Although the symptom score severity was slightly but significantly associated with alterations to QoL, it was not possible to determine a threshold for symptom scores that predict an alteration to QoL. Therefore, the evaluation of QoL in parallel to the assessment of the symptom score is required to endorse the entire spectrum of the severity of CC or FI.

Identifiants

pubmed: 32627072
doi: 10.1007/s00384-020-03685-w
pii: 10.1007/s00384-020-03685-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2041-2048

Auteurs

Dann Joseph Ouizeman (DJ)

Digestive Center, University Hospital of Nice, 151 route de Saint Antoine de Ginestière - CS 23079, 06202, Nice Cedex, France. ouizeman.d@chu-nice.fr.

Eugenia Marine-Barjoan (E)

Public Health Department, University Hospital of Nice, Nice, France.

Audrey Hastier-De Chelles (A)

Digestive Center, University Hospital of Nice, 151 route de Saint Antoine de Ginestière - CS 23079, 06202, Nice Cedex, France.

Marie De Matharel (M)

Digestive Center, University Hospital of Nice, 151 route de Saint Antoine de Ginestière - CS 23079, 06202, Nice Cedex, France.

Marie-Lise Montoya (ML)

Digestive Center, University Hospital of Nice, 151 route de Saint Antoine de Ginestière - CS 23079, 06202, Nice Cedex, France.

Rodolphe Anty (R)

Digestive Center, University Hospital of Nice, 151 route de Saint Antoine de Ginestière - CS 23079, 06202, Nice Cedex, France.
Faculty of Medicine, University of Nice - Côte d'Azur, Nice, France.
U1065, C3M, Team 8, Chronic Liver Diseases Associated with Obesity and Alcohol, National Institute of Health and Medical Research (INSERM), Nice, France.

Thierry Piche (T)

Digestive Center, University Hospital of Nice, 151 route de Saint Antoine de Ginestière - CS 23079, 06202, Nice Cedex, France.
Faculty of Medicine, University of Nice - Côte d'Azur, Nice, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH